{"id":50652,"date":"2023-08-20T01:35:07","date_gmt":"2023-08-20T05:35:07","guid":{"rendered":"https:\/\/ifintechworld.com\/investing\/neurocrine-biosciences-ingrezza-gets-fda-approval\/"},"modified":"2023-08-20T01:35:09","modified_gmt":"2023-08-20T05:35:09","slug":"neurocrine-biosciences-ingrezza-gets-fda-approval","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=50652","title":{"rendered":"Neurocrine Biosciences’ Ingrezza Gets FDA Approval"},"content":{"rendered":"
\n

By Brenda Le\u00f3n<\/p>\n

Neurocrine Biosciences said Friday the Food and Drug Administration approved Ingrezza capsules to treat adults with chorea, an abnormal involuntary movement disorder associated with Huntington’s disease.<\/p>\n

The San Diego-based biopharmaceutical company said the FDA approval is supported by data from two clinical studies conducted in collaboration with the Huntington Study Group.<\/p>\n

\n

Huntington’s disease is a hereditary progressive neurodegenerative disorder in which the loss of certain neurons within the brain causes motor, cognitive and psychiatric symptoms.<\/p>\n

Most people with the disease experience chorea, which is characterized by irregular and unpredictable movements. Chorea can affect various parts of the body and interfere with motor coordination, gait, swallowing and speech.<\/p>\n

Huntington’s disease affects an estimated 41,000 adults in the U.S., with more than 200,000 at risk of inheriting the disease, Neurocrine Biosciences said.<\/p>\n

Write to Brenda Le\u00f3n at brenda.leon@wsj.com<\/p>\n

<\/pre>\n<\/p><\/div>\n<\/div>\n
Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"
By Brenda Le\u00f3n Neurocrine Biosciences said Friday the Food and Drug Administration approved Ingrezza capsules to treat adults with chorea, an abnormal involuntary movement disorder associated with Huntington’s disease. The San Diego-based biopharmaceutical company said the FDA approval is supported by data from two clinical studies conducted in collaboration with the Huntington Study Group. Huntington’s […]<\/p>\n","protected":false},"author":1,"featured_media":1898,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"video","meta":{"footnotes":""},"categories":[239],"tags":[83],"class_list":["post-50652","post","type-post","status-publish","format-video","has-post-thumbnail","hentry","category-investing","tag-featured","post_format-post-format-video"],"yoast_head":"\nNeurocrine Biosciences' Ingrezza Gets FDA Approval | iFintechWorld<\/title>\n<meta name=\"description\" content=\"By Brenda Le\u00f3n Neurocrine Biosciences said Friday the Food and Drug Administration approved Ingrezza capsules to treat adults with chorea, an abnormal\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=50652\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurocrine Biosciences' Ingrezza Gets FDA Approval | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"By Brenda Le\u00f3n Neurocrine Biosciences said Friday the Food and Drug Administration approved Ingrezza capsules to treat adults with chorea, an abnormal\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=50652\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-20T05:35:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-20T05:35:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/mw_logo_social.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=50652#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=50652\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Neurocrine Biosciences’ Ingrezza Gets FDA Approval\",\"datePublished\":\"2023-08-20T05:35:07+00:00\",\"dateModified\":\"2023-08-20T05:35:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=50652\"},\"wordCount\":157,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"Investing\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=50652#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=50652\",\"url\":\"https:\/\/ifintechworld.com\/?p=50652\",\"name\":\"Neurocrine Biosciences' Ingrezza Gets FDA Approval | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2023-08-20T05:35:07+00:00\",\"dateModified\":\"2023-08-20T05:35:09+00:00\",\"description\":\"By Brenda Le\u00f3n Neurocrine Biosciences said Friday the Food and Drug Administration approved Ingrezza capsules to treat adults with chorea, an abnormal\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=50652#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=50652\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=50652#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurocrine Biosciences’ Ingrezza Gets FDA Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neurocrine Biosciences' Ingrezza Gets FDA Approval | iFintechWorld","description":"By Brenda Le\u00f3n Neurocrine Biosciences said Friday the Food and Drug Administration approved Ingrezza capsules to treat adults with chorea, an abnormal","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=50652","og_locale":"en_US","og_type":"article","og_title":"Neurocrine Biosciences' Ingrezza Gets FDA Approval | iFintechWorld","og_description":"By Brenda Le\u00f3n Neurocrine Biosciences said Friday the Food and Drug Administration approved Ingrezza capsules to treat adults with chorea, an abnormal","og_url":"https:\/\/ifintechworld.com\/?p=50652","og_site_name":"iFintechWorld","article_published_time":"2023-08-20T05:35:07+00:00","article_modified_time":"2023-08-20T05:35:09+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/mw_logo_social.png","type":"image\/png"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=50652#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=50652"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Neurocrine Biosciences’ Ingrezza Gets FDA Approval","datePublished":"2023-08-20T05:35:07+00:00","dateModified":"2023-08-20T05:35:09+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=50652"},"wordCount":157,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["Investing"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=50652#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=50652","url":"https:\/\/ifintechworld.com\/?p=50652","name":"Neurocrine Biosciences' Ingrezza Gets FDA Approval | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2023-08-20T05:35:07+00:00","dateModified":"2023-08-20T05:35:09+00:00","description":"By Brenda Le\u00f3n Neurocrine Biosciences said Friday the Food and Drug Administration approved Ingrezza capsules to treat adults with chorea, an abnormal","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=50652#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=50652"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=50652#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Neurocrine Biosciences’ Ingrezza Gets FDA Approval"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/50652","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50652"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/50652\/revisions"}],"predecessor-version":[{"id":50653,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/50652\/revisions\/50653"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/1898"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}